Concepedia

Katrine Ingelshed

KI

Statistics

Publications

4

Citations

58

H-Index

4

Active since

2020

Affiliations

Karolinska Institutet(Current)

Karolinska University Hospital

Uppsala University

Katrine Ingelshed is an author at Karolinska Institutet specializing in oncology, p53 inactivation, and p53 mutation.

Publications per year

2020–2024

4

Publications

4

Combined proinflammatory cytokine and cognate activation of invariant natural killer T cells enhances anti-DNA antibody responses

Saikiran K. Sedimbi, Thomas Hägglöf, Manasa G. Garimella et al. · Proceedings of the National Academy of Sciences · 2020 · 17 citations · Full text

, , +17

MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors

Katrine Ingelshed, Marit M. Melssen, Pavitra Kannan et al. · iScience · 2024 · 15 citations · Full text

, , +17

The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy

Katrine Ingelshed, Diana Spiegelberg, Pavitra Kannan et al. · Cancer Research Communications · 2022 · 14 citations · Full text

, , +17

MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia

Ada Lerma Clavero, Paula Lafqvist Boqvist, Katrine Ingelshed et al. · Scientific Reports · 2023 · 12 citations · Full text

, , +16

1–4 of 4